Trading of Disc Medicine was halted at 06:55 AM EST due to "News Pending". Trending NewsTrending NewsNASDAQ:IRON Disc Medicine (IRON) Stock Price, News & Analysis $78.94 +22.10 (+38.89%) As of 02:20 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Disc Medicine Stock (NASDAQ:IRON) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Disc Medicine alerts:Sign Up Key Stats Today's Range$69.98▼$80.2250-Day Range$55.74▼$82.6752-Week Range$40.00▼$99.50Volume6.85 million shsAverage Volume605,405 shsMarket Capitalization$302.75 millionP/E RatioN/ADividend YieldN/APrice Target$112.40Consensus RatingModerate Buy Company Overview Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. The company’s research centers on disorders involving the production of red blood cells, iron metabolism and heme biology, areas that can contribute to anemia and other blood-related complications. Disc Medicine’s lead product candidate is bitopertin, an oral small-molecule therapy designed to modulate glycine transporter 1 and influence heme production. The company is evaluating bitopertin in conditions including erythropoietic protoporphyria, a rare disorder associated with painful light sensitivity, as well as polycythemia vera and other hematologic diseases. The company is also developing additional therapies intended to regulate iron availability and address anemia associated with chronic or hematologic conditions. Disc Medicine is headquartered in Cambridge, Massachusetts, and conducts clinical development activities primarily through research and clinical-trial networks. The company is led by President and Chief Executive Officer John Quisel and trades on the Nasdaq under the symbol IRON.AI Generated. May Contain Errors. Read More Disc Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreIRON MarketRank™: 2.589108254935 of 5 starsDisc Medicine scored higher than 52% of companies evaluated by MarketBeat, and ranked 539th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingDisc Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on no strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialDisc Medicine has a consensus price target of $110.40, representing about 38.8% upside from its current price of $79.51.Amount of Analyst CoverageDisc Medicine has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Disc Medicine's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Disc Medicine are expected to decrease in the coming year, from ($6.61) to ($7.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Disc Medicine is -12.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Disc Medicine is -12.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDisc Medicine has a P/B Ratio of 4.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Disc Medicine's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.68% of the float of Disc Medicine has been sold short.Short Interest Ratio / Days to CoverDisc Medicine has a short interest ratio ("days to cover") of 12.79, which indicates bearish sentiment.Change versus previous monthShort interest in Disc Medicine has recently increased by 0.87%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDisc Medicine does not currently pay a dividend.Dividend GrowthDisc Medicine does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.55 News SentimentDisc Medicine has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Disc Medicine this week, compared to 8 articles on an average week.Search Interest6 people have searched for IRON on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows1 people have added Disc Medicine to their MarketBeat watchlist in the last 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Disc Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,239,760.00 in company stock.Percentage Held by Insiders3.76% of the stock of Disc Medicine is held by insiders.Percentage Held by Institutions83.70% of the stock of Disc Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Disc Medicine's insider trading history. Receive IRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Disc Medicine and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IRON Stock News HeadlinesDisc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study1 hour ago | benzinga.comDisc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes2 hours ago | barrons.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 19 at 1:00 AM | Stansberry Research (Ad)Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints2 hours ago | proactiveinvestors.comDisc Medicine Set To Report Phase 3 Bitopertin Results In Rare Blood Disorder; Stock Up4 hours ago | rttnews.comDisc Medicine Says Metabolic Disorder Drug Meets Main Goal in Phase 3 Trial; Shares Rise Pre-Bell4 hours ago | finance.yahoo.comDisc Medicine's Bitopertin Meets All Phase 3 Goals; FDA Resubmission Planned4 hours ago | rttnews.comDisc Medicine rallies 32% as investors await Bitopertin trial results4 hours ago | seekingalpha.comSee More Headlines IRON Stock Analysis - Frequently Asked Questions How have IRON shares performed this year? Disc Medicine's stock was trading at $79.41 at the beginning of the year. Since then, IRON shares have increased by 0.1% and is now trading at $79.5130. How were Disc Medicine's earnings last quarter? Disc Medicine, Inc. (NASDAQ:IRON) released its earnings results on Thursday, July, 30th. The company reported ($1.54) earnings per share for the quarter, beating analysts' consensus estimates of ($1.71) by $0.17. When did Disc Medicine IPO? Disc Medicine (IRON) raised $105 million in an IPO on Wednesday, August 12th 2020. The company issued 10,500,000 shares at a price of $10.00 per share. Who are Disc Medicine's major shareholders? Top institutional investors of Disc Medicine include Assenagon Asset Management S.A. (2.92%). Insiders that own company stock include Venture Fund X LP Atlas, Orbimed Advisors Llc, John D Quisel, Mona Ashiya, Pamela Stephenson, William Jacob Savage, Jean M Franchi, Jonathan Yen-Wen Yu, Rahul Khara, Kevin Bitterman, Joanne Bryce and William Richard White. View institutional ownership trends. How do I buy shares of Disc Medicine? Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Disc Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Disc Medicine investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Oracle (ORCL), Taiwan Semiconductor Manufacturing (TSM), Intuitive Surgical (ISRG) and Kratos Defense & Security Solutions (KTOS). Company Calendar Last Earnings7/30/2026Today10/19/2026Study result10/19/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 6 days, IRON's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IRON CIK1816736 Webwww.discmedicine.com Phone(617) 674-9274FaxN/AEmployees165Year Founded2017Price Target and Rating Average Price Target for Disc Medicine$112.40 High Price Target$170.00 Low Price Target$83.00 Potential Upside/Downside+44.5%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($6.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$212.18 million Net MarginsN/A Pretax MarginN/A Return on Equity-37.17% Return on Assets-33.65% Debt Debt-to-Equity Ratio0.09 Current Ratio24.14 Quick Ratio24.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$19.52 per share Price / Book3.99Miscellaneous Outstanding Shares3,835,000Free Float36,949,000Market Cap$298.41 million OptionableNot Optionable Beta0.93 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:IRON) was last updated on 10/19/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Disc Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Disc Medicine With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
